[Novel Research Progress of the Recombinant Vaccine for MERS-CoV].
Identifieur interne : 001065 ( PubMed/Corpus ); précédent : 001064; suivant : 001066[Novel Research Progress of the Recombinant Vaccine for MERS-CoV].
Auteurs : Huizhen Hu ; Yuqing ShenSource :
- Bing du xue bao = Chinese journal of virology [ 1000-8721 ] ; 2016.
English descriptors
- KwdEn :
- Animals, Antibodies, Viral (immunology), Coronavirus Infections (immunology), Coronavirus Infections (prevention & control), Coronavirus Infections (virology), Humans, Middle East Respiratory Syndrome Coronavirus (genetics), Middle East Respiratory Syndrome Coronavirus (immunology), Vaccines, Synthetic (administration & dosage), Vaccines, Synthetic (genetics), Vaccines, Synthetic (immunology), Viral Vaccines (administration & dosage), Viral Vaccines (genetics), Viral Vaccines (immunology).
- MESH :
- chemical , administration & dosage : Vaccines, Synthetic, Viral Vaccines.
- chemical , genetics : Vaccines, Synthetic, Viral Vaccines.
- chemical , immunology : Antibodies, Viral, Vaccines, Synthetic, Viral Vaccines.
- genetics : Middle East Respiratory Syndrome Coronavirus.
- immunology : Coronavirus Infections, Middle East Respiratory Syndrome Coronavirus.
- prevention & control : Coronavirus Infections.
- virology : Coronavirus Infections.
- Animals, Humans.
Abstract
Respiratory syndrome coronavirus in the Middle East (MERS-Co V) has caused wide attention since it was discovered, and the design of effective vaccines for MERS-Co V becomes a hot area at present. Therefore, this review is aimed at novel research progress of the recombinant vaccine for MERS-Co V, including selection and improvement of animal model for vaccine test,construction and optimization of recombinant subunit vaccine, attempts at recombinant live vector vaccine based on varies of vectors, as well as the advantages of pseudovirus. In conclusion, we make a summary about the novel research progress of the recombinant vaccine for MERS-Co V and a promising prospect of its development in terms of both safety and effectiveness verification in the future will be demonstrated.
PubMed: 29995374
Links to Exploration step
pubmed:29995374Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Novel Research Progress of the Recombinant Vaccine for MERS-CoV].</title><author><name sortKey="Hu, Huizhen" sort="Hu, Huizhen" uniqKey="Hu H" first="Huizhen" last="Hu">Huizhen Hu</name></author><author><name sortKey="Shen, Yuqing" sort="Shen, Yuqing" uniqKey="Shen Y" first="Yuqing" last="Shen">Yuqing Shen</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:29995374</idno><idno type="pmid">29995374</idno><idno type="wicri:Area/PubMed/Corpus">001065</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001065</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Novel Research Progress of the Recombinant Vaccine for MERS-CoV].</title><author><name sortKey="Hu, Huizhen" sort="Hu, Huizhen" uniqKey="Hu H" first="Huizhen" last="Hu">Huizhen Hu</name></author><author><name sortKey="Shen, Yuqing" sort="Shen, Yuqing" uniqKey="Shen Y" first="Yuqing" last="Shen">Yuqing Shen</name></author></analytic><series><title level="j">Bing du xue bao = Chinese journal of virology</title><idno type="ISSN">1000-8721</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Viral (immunology)</term><term>Coronavirus Infections (immunology)</term><term>Coronavirus Infections (prevention & control)</term><term>Coronavirus Infections (virology)</term><term>Humans</term><term>Middle East Respiratory Syndrome Coronavirus (genetics)</term><term>Middle East Respiratory Syndrome Coronavirus (immunology)</term><term>Vaccines, Synthetic (administration & dosage)</term><term>Vaccines, Synthetic (genetics)</term><term>Vaccines, Synthetic (immunology)</term><term>Viral Vaccines (administration & dosage)</term><term>Viral Vaccines (genetics)</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Vaccines, Synthetic</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Vaccines, Synthetic</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Viral</term><term>Vaccines, Synthetic</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Coronavirus Infections</term><term>Middle East Respiratory Syndrome Coronavirus</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Respiratory syndrome coronavirus in the Middle East (MERS-Co V) has caused wide attention since it was discovered, and the design of effective vaccines for MERS-Co V becomes a hot area at present. Therefore, this review is aimed at novel research progress of the recombinant vaccine for MERS-Co V, including selection and improvement of animal model for vaccine test,construction and optimization of recombinant subunit vaccine, attempts at recombinant live vector vaccine based on varies of vectors, as well as the advantages of pseudovirus. In conclusion, we make a summary about the novel research progress of the recombinant vaccine for MERS-Co V and a promising prospect of its development in terms of both safety and effectiveness verification in the future will be demonstrated.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29995374</PMID><DateCompleted><Year>2018</Year><Month>07</Month><Day>31</Day></DateCompleted><DateRevised><Year>2018</Year><Month>07</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1000-8721</ISSN><JournalIssue CitedMedium="Print"><Volume>32</Volume><Issue>4</Issue><PubDate><Year>2016</Year><Month>07</Month></PubDate></JournalIssue><Title>Bing du xue bao = Chinese journal of virology</Title><ISOAbbreviation>Bing Du Xue Bao</ISOAbbreviation></Journal><ArticleTitle>[Novel Research Progress of the Recombinant Vaccine for MERS-CoV].</ArticleTitle><Pagination><MedlinePgn>495-500</MedlinePgn></Pagination><Abstract><AbstractText>Respiratory syndrome coronavirus in the Middle East (MERS-Co V) has caused wide attention since it was discovered, and the design of effective vaccines for MERS-Co V becomes a hot area at present. Therefore, this review is aimed at novel research progress of the recombinant vaccine for MERS-Co V, including selection and improvement of animal model for vaccine test,construction and optimization of recombinant subunit vaccine, attempts at recombinant live vector vaccine based on varies of vectors, as well as the advantages of pseudovirus. In conclusion, we make a summary about the novel research progress of the recombinant vaccine for MERS-Co V and a promising prospect of its development in terms of both safety and effectiveness verification in the future will be demonstrated.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Huizhen</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Yuqing</ForeName><Initials>Y</Initials></Author></AuthorList><Language>chi</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Bing Du Xue Bao</MedlineTA><NlmUniqueID>8803009</NlmUniqueID><ISSNLinking>1000-8721</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065207" MajorTopicYN="N">Middle East Respiratory Syndrome Coronavirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>7</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29995374</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001065 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001065 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:29995374
|texte= [Novel Research Progress of the Recombinant Vaccine for MERS-CoV].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:29995374" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |